title: Discontinuing antithyroid drug therapy before ablation with radioiodine in Graves disease.
abstract: OBJECTIVE
  To determine the relative effects on thyroid hormone levels of discontinuing antithyroid drug therapy and subsequent ablation with radioiodine in patients with hyperthyroid Graves disease.
  
  
  METHODS
  A clinical trial with a prospective analysis of the relative change in thyroid hormone levels over time in response to therapy in two study groups.
  
  
  METHODS
  An outpatient endocrine clinic at a tertiary care hospital.
  
  
  METHODS
  21 patients with a clinical diagnosis of hyperthyroid Graves disease scheduled to receive ablation therapy with radioiodine (131I): 17 patients were pretreated with antithyroid drugs, and 4 were not.
  
  
  METHODS
  Antithyroid drugs were stopped 6 days before radioiodine therapy. Patients were monitored clinically and biochemically with measurement of free and total levels of thyroxine (T4) and triiodothyronine (T3) on days -6, -3, -1; the day of radioiodine therapy; and days 1, 2, 3, 4, 5, 7, and 14.
  
  
  RESULTS
  Before radioiodine treatment and compared with baseline measurement, the mean increase in free T4 levels after discontinuation of antithyroid therapy was 86% (95% CI, 16.1% to 156%), with a concurrent mean increase in free T3 levels of 71.6% (CI, 31% to 112%). Radioiodine therapy resulted in a mean decrease in free T3 levels of 28.7% (CI, -44.1% to -13.2%), a mean decrease in total T3 levels of 22.9% (CI, -39.4% to -6.4%), and stability in free and total T4 levels rather than aggravation of thyrotoxicosis. A smaller group of patients not receiving antithyroid drugs experienced a course qualitatively similar to that of pretreated patients after 131I treatment, with a mean reduction in free T4 levels of 39.8% (CI, -69.9% to -9.7%) and a mean decrease in free T3 levels of 49.4% (CI, -93.7% to -5.1%).
  
  
  CONCLUSIONS
  Short-term increases in thyroid hormone levels in patients with Graves disease receiving radioiodine ablation occur primarily as a result of discontinuing antithyroid therapy rather than as a result of treatment with 131I. Stability or decrease in thyroid hormone levels, rather than further elevation, occurs during the 2-week interval after ablation therapy with 131I. Antithyroid drug therapy before radioiodine ablation may have little effect on the short-term biochemical course after 131I therapy for Graves disease. The homogeneity of our sample regarding age, diagnosis, and general health may prevent application of these findings to other populations without further study.
authors.affiliation: Walter Reed Army Medical Center, Washington, D.C.
authors.forename: H B
authors.initials: HB
authors.lastname: Burch
authors.forename: B L
authors.initials: BL
authors.lastname: Solomon
authors.forename: L
authors.initials: L
authors.lastname: Wartofsky
authors.forename: K D
authors.initials: KD
authors.lastname: Burman
mesh_terms: D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000008:administration & dosage*; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013963:Thyroid Hormones / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D013963:Thyroid Hormones